Mitochondrial ROS and cancer drug resistance: Implications for therapy

Pharmacological Research

Volumn 100, Issue , 2015, Pages 170-174

  Okon, Imoh S ^a   Zou, Ming Hui ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Cancer drug resistance; Metabolic alterations; Mitochondrial ROS; Oxidative stress

Indexed keywords

ANTINEOPLASTIC AGENT; GEFITINIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MITOCHONDRIAL ENZYME; REACTIVE OXYGEN METABOLITE;

CANCER CELL; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CELL FUNCTION; CELL METABOLISM; CELL ORGANELLE; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MITOCHONDRION; OXIDATION REDUCTION STATE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; METABOLISM; NEOPLASM; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PHYSIOLOGY;

DRUG RESISTANCE, NEOPLASM; HUMANS; MITOCHONDRIA; NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84940030548     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.06.013     Document Type: Review

References (30)

1. J.K. Kwee A Paradoxical chemoresistance and tumor suppresive role of antioxidant in solid cancer cells: a strange case of Dr. Jekyll and Mr. Hyde Biomed. Res. Int. 2014 2014 1 9
2. G. Chen, F. Wang, D. Trachootham, and et al. Preferential killing of cancer cells with mitochondrial dysfunction by natural compounds Mitochondrion 10 6 2010 614 625
3. J. Chen. Reactive oxygen species and drug resistance in cancer chemotherapy Austin J. Clin. Pathol. 1 14 2014 1 8
4. L. Poillet-Perez, G. Despouy, R. Delage-Mourroux, and et al. Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy Redox Biol. 4 2015 184 192
5. S. Toyokuni Molecular mechanisms of oxidative stress-induced carcinogenesis: from epidemiology to oxygenomics IUBMB Life 60 7 2008 441 447
6. I.S. Okon, K.A. Coughlan, M. Zhang, and et al. Gefitinib-mediated ROS instigates mitochondrial dysfunction and drug resistance in lung cancer cells J. Biol. Chem. 290 14 2015 9101 9110
7. M. Zeisberg, and E.G. Neilson Biomarkers for epithelial-mesenchymal transitions J. Clin. Invest. 119 6 2009 1429 1437
8. T. Arumugam, V. Ramachandran, K.F. Fournier, and et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer Cancer Res. 69 14 2009 5820 5828
9. C.L. Sommers, S.E. Heckford, J.M. Skerker, and et al. Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines Cancer Res. 52 1992 5190 5197
10. A. Voulgari, and A. Pintzas Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic Biochim. Biophys. Acta 1796 2 2009 75 90
11. E.W. Thompson, J. Torri, M. Sabol, and et al. Oncogene-induced basement membrane invasiveness in human mammary epithelial cells Clin. Exp. Metastasis 12 3 1994 181 194
12. J. Ma, C. Dong, and C. Ji. MicroRNA and drug resistance Cancer Gene Ther. 17 8 2010 523 531
13. S. Majumder, and S.T. Jacob Emerging role of microRNAs in drug-resistant breast cancer Gene Expr. 15 3 2011 141 151
14. A.A. Dayem, H.-Y. Choi, J.-H. Kim, and et al. Role of oxidative stress in stem, cancer, and cancer stem cells Cancers 2 2 2010 859 884
15. M. Valko, C.J. Rhodes, J. Moncol, and et al. Free radicals, metals and antioxidants in oxidative stress-induced cancer Chem. Biol. Interact. 160 1 2006 1 40
16. S.S. Sabharwal, and P.T. Schumacker Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? Nat. Rev. Cancer 14 11 2014 709 721
17. V.A. Kobliakov Mechanisms of tumor promotion by reactive oxygen species Biochemistry 75 6 2010 675 685
18. M. Jimenez-Del-Rio, and C. Velez-Pardo The bad, the good, and the ugly about oxidative stress Oxid. Med. Cell Longev. 2012 2012 1 13
19. B.F. Oliveira, J.A. Nogueira-Machado, and M.M. Chaves The role of oxidative stress in the aging process Sci. World J. 10 2010 1121 1128
20. Y. Dong, M. Zhang, B. Liang, and et al. Reduction of amp-activated protein kinase alpha2 increases. endoplasmic reticulum stress and atherosclerosis in vivo Circulation 121 6 2010 792 803
21. S. Wang, M. Zhang, B. Liang, and et al. Ampkalpha2 deletion causes aberrant expression and activation.of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26s proteasomes Cir. Res. 106 6 2010 1117 1128
22. W.V. Veelen, S.E. Korsse, L.V.D. Laar, and et al. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling Oncogene 30 20 2010 2289 2303
23. E. Giannoni, T. Fiaschi, G. Ramponi, and et al. Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals Oncogene 28 20 2009 2074 2086
24. I. Dolado, A. Swat, N. Ajenjo, and et al. p38a MAP kinase as a sensor of reactive oxygen species in tumorigenesis Cancer Cell 11 2 2007 191 205
25. C. Runchel, A. Matsuzawa, and H. Ichijo Mitogen-activated protein kinases in mammalian oxidative stress responses Antioxid. Redox Signal. 15 1 2011 205 218
26. O. Warburg On the origin of cancer cells Science 123 3191 1956 309 314
27. P.S. Ward, and C.B. Thompson Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate Cancer Cell 21 3 2012 297 308
28. V. Gogvadze Targeting mitochondria in fighting cancer Curr. Pharm. Des. 17 36 2011 4034 4046
29. D. Trachootham, J. Alexandre, and P. Huang Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 8 7 2009 579 591
30. S. Wen, D. Zhu, and P. Huang Targeting cancer cell mitochondria as a therapeutic approach Future Med. Chem. 5 1 2013 53 67